registry – Page 42 – Communicable Diseases Research

Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-10-302022-10-29
Journal: Trials [Category] Coronavirus, MERS, SARS,

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-272022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 Adverse drug reaction allergy allocation sequence antibody tests anticipated Arm ARMS assigned Bandar Abbas Blinding block randomization Breastfeeding carried China cirrhosis clinical Clinical improvement company Computed tomography conditions Confirmed Control control group Controlled trial COVID-19 criteria Critical Department Diagnosis dissemination dose Efficacy and safety element evaluate Favipiravir Fever FIVE generate Hepatitis history Hospital stay Hospitalization ill patient in both groups incidence India infection with SARS-CoV-2 interferon intervention group Iran liver diseases Lopinavir/ritonavir nasopharyngeal sample number objective Open-label Other outcome parallel-group participant Patient patients Phase 3 Placebo Pneumonia polymerase chain Primary outcome protocol random randomization Randomized Randomized controlled trial receive registry renal respiratory routine care RT-PCR Sample size SARS-CoV-2 screened secondary outcome single-center Study protocol treatment arm Trial trial protocol two group Viral load web-based system website X-ray Zhejiang
[DOI] 10.1186/s13063-020-04747-8 PMC 바로가기 [Article Type] Letter

Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-272022-10-29
Journal: Trials [Category] Coronavirus, MERS, SARS,

[키워드] 1:1 accompany age Antibody test anticipated assessment assigned blinded block Boron-containing compounds Breastfeeding C-reactive protein C-reactive protein (CRP calculated CBC center clinical Clinical symptoms clinical trial complete blood count Compound computer-generated conducted COVID-19 Critical Data analysis diagnosis of SARS-CoV-2 dissemination double-blind dry cough element erythrocyte sedimentation rate ESR exclusion criteria fatigue Features female Fever four groups group groups Imam include inclusion criteria Infection information Intervention investigator Iran male Medical Sciences number nutrition objective Oleoylethanolamide outcome participant Patient patients patients with COVID-19 PCR placebo-controlled clinical trial Pneumonia polymerase chain Pregnancy primary end point profile protocol randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly receive Registered registry Reza Sample size single-center status Study protocol subject Tabriz total sample size Treatment Trial university Version website
[DOI] 10.1186/s13063-020-04820-2 PMC 바로가기 [Article Type] Letter

Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

중등도의 COVID-19 환자에서 멜라토닌의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-262022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 acute respiratory syndrome Adverse drug reaction Adverse drug reactions alcohol All study participants allergy allocation sequence Alpha anticipated Antiviral Arm ARMS assigned Bandar Abbas blinded Blinding block randomization Breastfeeding C-reactive protein Chain Reaction chronic hepatitis cirrhosis clinical clinical symptom Clinical symptoms clinical trials Clinicians Computed tomography conducted Confirmed Control control group Corticosteroids COVID-19 COVID-19 pneumonia criteria Critical Department Depression diabetes Diabetes Mellitus Diagnosis Diseases dissemination dose double-blind drug drugs education Efficacy and safety element evaluate exclusion criteria faculty feature generate Hepatitis history Hospitalization Hospitalized hypertension IL-1β IL-6 ill patient IMPROVE incidence inclusion criteria inflammatory parameter inflammatory parameters Inflammatory responses Informed consent interleukin interleukin-1β Iran liver diseases Medical Sciences Medicines melatonin Ministry of Health number Nurses objective outcome oxygen oxygen saturation parallel-group participant Participants Patient patients patients randomized pharmaceutical Pharmacy Placebo placebo-controlled clinical trial Pneumonia polymerase chain polymerase chain reaction polymerase chain reaction) positive Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial regimen Registered registration date registration number registry Research respiratory Sample size SARS-CoV-2 screened secondary outcome Secondary outcomes Seizure serum Seven Severe acute respiratory syndrome single-center standard treatment status Study protocol the Faculty therapeutic treatment arm trial protocol Trial registration Tumor tumor necrosis tumor necrosis factor tumor necrosis factor-alpha two group two groups underlying diseases university Version Warfarin web-based system website X-ray
[DOI] 10.1186/s13063-020-04737-w PMC 바로가기 [Article Type] Letter

Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis

Research Article

Published on 2020-10-232022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] 95% CI Adults age Asian collected data COVID-19 Data analysis disease effort England Evidence feature General population Haemodialysis highest individual Mortality outcomes Patient patients with COVID-19 positive positive COVID-19 PROTECT registry retrospective cohort study risk risk factor Support survival Treatment
[DOI] 10.1371/journal.pone.0241263 PMC 바로가기 [Article Type] Research Article

Neonatal Infection Due to SARS-CoV-2: An Epidemiological Study in Spain

Pediatrics

Published on 2020-10-232022-10-31
Journal: Frontiers in Pediatrics [Category] COVID-19,

[키워드] acute respiratory syndrome Administered Admission age asymptomatic patient both groups Care caused Characteristics Clinical characteristics clinical manifestation clinical manifestations collected Community community-acquired infection complementary coronavirus Coronavirus disease 2019 COVID-19 Diagnosis epidemiology–descriptive Evidence febrile gastroenteritis generally mild Health healthcare worker hospital discharge Hospital stay Hospital-acquired infection Hospitalization in both groups Infection information intensive care management MOST National Neonatal Neonate Neonates neonatology Newborn NICU nosocomial nosocomial COVID-19 occurred Pathologies Patient patients pediatric performed prospective epidemiological study Registered registry required Respiratory Support SARS-CoV-2 SARS-COV-2 infection Severe case Society source of infection Spain Spanish supported syndrome Transmission Treatment upper respiratory airway was performed
[DOI] 10.3389/fped.2020.580584 PMC 바로가기 [Article Type] Pediatrics

The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial

COVID-19 환자의 치료 보조제로 커큐민을 함유한 나노 미셀의 임상 효과 및 치료 후 면역 반응 균형 변화: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-222022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 accompany addition allergy assigned balance Bandar Abbas bedtime blind Blinding both groups breakfast Capsule change Characteristics chronic chronic obstructive pulmonary disease clinical Clinical effect clinical examination clinical examinations clinical symptom clinical trial clinical trials Comorbidities Comorbidity company comparator Complete computer conducted congestive heart failure control group COVID-19 COVID-19 patient COVID-19 patients Curcumin Cytokines digit digits dinner dissemination Effectiveness element evaluate evaluated expected expression filtration filtration rate FOXP3 gallstone gastritis GATA Gender Gene Expression glomerular filtration rate heart failure history IFN-γ IL-17 IL-4 immune response immune responses in both group inclusion criteria Inflammatory marker inflammatory markers information Interleukins intervention group Iran kPa Laboratory laboratory findings laboratory technician laboratory technicians lactation less liver liver failure Lymphocytes number Nurses objective Obstructive obstructive pulmonary disease outcome PaO2 parallel group participant Participation Patient patients patients with COVID-19 per day performed Peripheral blood physician Placebo placebo group placebo-controlled positive COVID-19 post treatment Pregnancy protocol pulmonary disease random randomisation randomised randomised controlled trial randomization Randomized randomized clinical trial Randomly real time PCR recorded recruitment Registered registry Regulatory renal renal failure routine standard treatment Sample size sealed selected serum cytokine serum cytokines Serum level serum parameter serum parameters shift single-center statisticians Study protocol T helper TGF-β the placebo group therapeutic Treatment Trial Trial registration ventilator Version website written consent
[DOI] 10.1186/s13063-020-04824-y PMC 바로가기 [Article Type] Letter

Treatment of out-of-hospital cardiac arrest in the COVID-19 era: A 100 days experience from the Lombardy region

Research Article

Published on 2020-10-222022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

중증 코로나바이러스 질환의 치료를 위한 정맥 면역글로불린 감마의 사용 2019: 무작위 위약 대조 이중 맹검 임상 시험

Research Article

Published on 2020-10-212022-08-13
Journal: BMC Infectious Diseases [Category] MERS, SARS, 임상,

[키워드] accompany addition administration assigned clinical Clinical characteristics Clinical outcome clinical trial clinical trials conducted control group coronavirus disease Coronavirus disease 2019 country COVID-19 COVID-19 infection demographics demonstrated disease double-blind effective Efficacy evaluate Immunoglobulin IMPROVE in-hospital mortality in-hospital mortality rate information initial initial treatment initial treatment) initial treatments Intravenous immunoglobulin IVIG Laboratory Laboratory test Laboratory tests medication mortality rate multicenter multivariate regression analysis Occurrence Patient Placebo placebo-controlled Randomized Randomly reduce mortality rate Registered registry required respond Result Sample size severe cases severe coronavirus disease Severe COVID-19 Infection Severe infection significantly significantly lower standard treatment statistically Study protocol subject subjects Treatment two groups were recorded
[DOI] 10.1186/s12879-020-05507-4 PMC 바로가기 [Article Type] Research Article

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection – a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-202022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 2019-nCoV allergic Antipyretic Antiretroviral therapy Antiviral Arm as required assigned Breastfeeding Care categories cause clinical combination therapy compassionate use cough country COVID-19 COVID-19 infection criteria death defined described discharged disease dissemination drug Efficacy element eligibility criteria enrolled enrolment Etiquette exclusion criteria exploratory female Fever Frequency H1N1 hand hygiene Hydration Hydroxychloroquine ICU Patients inclusion criteria India Infection infection with SARS-CoV-2 investigator Laboratory Loading dose Lopinavir/ritonavir Lopinavir/Ritonavir combination mechanical ventilation medication Mortality non-ICU non-invasive ventilation Non-severe case Normalisation number nutrition objective off-label organ oxygen saturation paO2/fiO2 participant Participants Patient pharmacotherapy Placebo positive Precaution progression protocol QT prolongation randomisation randomised randomised controlled trial randomization Randomized controlled trial Randomly receipt recruitment regimen Registration registry replaced required Research respiratory rate ribavirin RT-PCR Safety Sample size SARS-CoV-2 RT-PCR screened secondary secure Serious Adverse Event Severe COVID-19 Infection Severe patient severity specimen Standard standard treatment status stratified study period Study protocol supplemental oxygen Support Suppressant surgical sustained symptomatic patient Tablet tested the patient therapeutic intervention therapy time time to defervescence treated Treatment treatment arm treatment group Trial upper respiratory tract Vasopressor Ventilation ventilator wear website
[DOI] 10.1186/s13063-020-04774-5 PMC 바로가기 [Article Type] Letter